Skip to content

A randomized, double-blind, placebo-controlled trial of the efficacy of ACNN15(R) vaccinium tablets as an intervention for cognitive function in a prediabetes population

A randomized, double-blind, placebo-controlled trial of the efficacy of vaccinium tablets as an intervention for cognitive function in a prediabetes population

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400086790
Enrollment
Unknown
Registered
2024-07-11
Start date
2024-07-15
Completion date
Unknown
Last updated
2024-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prediabetes

Interventions

Sponsors

School of Public Health, Wuhan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Age 18-70 years. (2) Prediabetes people with fasting blood glucose 5.6-7 mmol/L (100-126 mg/dL) or 2-hour postprandial blood glucose 7.8-11.1 mmol/L (140-200 mg/dL) or HbA1c 5.7%-6.4% are selected. (3) People who gave informed consent, volunteered to be tested, and ensured cooperation.

Exclusion criteria

Exclusion criteria: (1) Pregnant or lactating women. (2) Those who are allergic to dietary supplement. (3) Use of other vaccinium extract products. (4) Those who have taken other anti-glycation health food products in the last two weeks, and those who have already taken items related to the function of the test in a short period of time. (5) Recent (within the past 3 months) major trauma or surgical event. (6) Combination of serious diseases such as heart, cerebrovascular, liver, kidney, haematopoietic system, bronchial and lung diseases and mental diseases. (7) Failure to take the test samples as prescribed or adding other drugs midway, unable to judge the efficacy or incomplete information. (8) Diabetes patients or taking oral hypoglycemic agents or injecting insulin.

Design outcomes

Primary

MeasureTime frame
Cognitive function;

Secondary

MeasureTime frame
Brain structure and function;Dementia biomarker;Area under the curve during oral glucose tolerance test;Neuronal insulin resistance;Circulating advanced glycosylation end products concentrations;Circulating advanced glycosylation end products receptor concentrations;Fasting plasma glucose;Fasting insulin ;glycated hemoglobin (HbA1c);quantitative insulin sensitivity check index;

Countries

China

Contacts

Public ContactLuo Dan,Shuang Rong

School of Nursing, Wuhan University; School of Public Health, Wuhan University

luodan@whu.edu.cn+86 186 2774 0429

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026